Pentoxifylline (PTX) - An alternative treatment in Graves' ophthalmopathy (inactive phase): Assessment by a disease specific quality of life questionnaire and by exophthalmometry in a prospective randomized trial

Pentoxifylline (PTX) - An alternative treatment in Graves' ophthalmopathy (inactive phase): Assessment by a disease specific quality of life questionnaire and by exophthalmometry in a prospective randomized trial

Author Finamor Junior, Francisco Estivallet Autor UNIFESP Google Scholar
Martins, João Roberto Maciel Autor UNIFESP Google Scholar
Nakanami, Deise Mitsuko Autor UNIFESP Google Scholar
Paiva, Elias Rodrigues de Autor UNIFESP Google Scholar
Manso, Paulo Gois Autor UNIFESP Google Scholar
Furlanetto, Reinaldo Perrone Autor UNIFESP Google Scholar
Institution Universidade Federal de São Paulo (UNIFESP)
Abstract PURPOSE. To investigate the effect of pentoxifylline (PTX) in subjects with inactive Graves' ophthalmopathy (GO) through a specific quality of life (QOL) questionnaire and exophthalmometry readings.METHODS. Eighteen females were randomly divided in two groups. Group A (n=9) was treated with PTX 1200 mg orally/day for 6 months. Group B (n=9) received placebo during the initial 6 months and then PTX for another 6 months. Proptosis measurements were carried out every 3 months and a questionnaire graded from 0 to 10 according to the severity of the symptoms was performed at baseline and after placebo and PTX administration.RESULTS. At baseline, Group A questionnaire score values were 5.5 (median; range 3.5 to 8.0), and 5.0 after 6 months (3.0 to 6.0; p=0.01). In Group B, baseline values were not significantly different after 6 months of placebo: 6.0 (4.5 to 7.0) and 5.5 (4.5 to 7.0), respectively. However, a significant change was observed 6 months after PTX: 4.0 (2.0 to 5.0; p<0.001). Patients in Group A had a progressive improvement of proptosis during PTX: at baseline, 23 mm (median; range 20 to 32); after 3 months, 23 mm (18 to 30; p=0.02); and after 6 months, 23 mm (18 to 30; p=0.005). In Group B, proptosis remained stable during placebo: at baseline, 23 mm (21 to 25); after 3 months, 23 mm (20 to 25); and after 6 months, 23.5 mm (20 to 25). A significant change was observed after 3 and 6 months of PTX: 22 mm (19 to 24; p=0.0006) and 20.8 mm (17 to 25; p=0.0003), respectively.CONCLUSIONS. Pentoxifylline seems to improve the QOL of patients in the inactive phase of GO. The objective findings of the proptosis readings corroborate to suggest that PTX may be an effective and promising drug in the inactive phase of GO. 14: )
Keywords Graves' ophthalmopathy
pentoxifylline
Language English
Date 2004-07-01
Published in European Journal Of Ophthalmology. Milan: Wichtig Editore, v. 14, n. 4, p. 277-283, 2004.
ISSN 1120-6721 (Sherpa/Romeo, impact factor)
Publisher Wichtig Editore
Extent 277-283
Origin http://www.eur-j-ophthalmol.com/article/pentoxifylline--ptx---an-alternative-treatment-in-graves-ophthalmopathy--inactive-phase---assessment-by-a-disease-specific-quality-of-life-questionnai-art003007
Access rights Open access Open Access
Type Article
Web of Science ID WOS:000222980500001
URI http://repositorio.unifesp.br/11600/43617

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account